Interim report
Page 1
Interim Report May–July 2026
Page 2
Ongoing growth and improved results in the firstquarter of the year First quarter (May 1 - July 31, 2026) The number of S1 surgeries was 48 (41) Net sales increased by 27.0% to SEK 30.2 million (23.8) The Gross margin was 102% * (80%) EBITDA was SEK 3.8 million (-10.7) Operating pro t was SEK 1.3 million (-12.4) Operating cash ow was SEK -2.2 million (-9.5) * Gross margin exceeded 100% in the quarter due to a SEK 6,2 million refund of previously paid U.S. customs duties recognized in cost of goods sold. Adjusted for this item, the gross margin was 82%. Stage 1 (S1) 48 Surgeries Net sales 30.2 MSEK EBITDA 3.8 MSEK Operating cash ow -2.2 MSEK Quarter Highlights Higher S1 volumes in both market regions 48 S1 procedures (41) were performed during the quarter, up 17%. The U.S. accounted for 32 (27) and EMEA for 16 (14). Revenue growth across both market regions Net sales increased 27% to SEK 30.2 million (23.8). The U.S. grew 22% to SEK 23.5 million (19.3) and EMEA 51% to SEK 6.7 million (4.4). Higher margins and lower cost levels Excluding SEK 6.2 million in customs duty refunds, gross margin was 82% (80). Lower external and personnel expenses contributed to EBITDA of SEK 3.8 million (-10.7), or SEK -2.4 million excluding the refunds. "We will reach more patients, improve conversion and drive more S1 surgeries." Martin Hillsten / CEO Integrum | Interim Report May-July 2026 1
Page 3
From transformation to acceleration The rst quarter of our new nancial year clearly shows that Integrum continues to develop in the right direction. After a year marked by extensive changes, we now see how our strategic shift is starting to take e ect. The number of S1 surgeries continues to grow, revenue is increasing, and we report a positive EBITDA for the quarter. The development during the quarter shows that our strategic shift is starting to yield clear results. Through an increased commercial focus, a more e cient organization, and a lower cost base, we have created better conditions for both growth and pro tability. We have laid the foundation for building a scalable business where continued growth can be converted into long-term sustainable pro tability. More S1 operations drive our growth A total of 48 S1 surgeries were performed during the quarter, versus 41 in the same period last year — an increase of 17% and one of the highest levels in the history of the company. Net sales increased by 27% to SEK 30.2 million, compared with SEK 23.8 million in the same period last year. S1 is our most important operational metric. Every S1 surgery performed represents a new patient starting treatment with the OPRA Implant System, and lays the groundwork for revenue in the periods that follow. The continued positive development in S1 volumes, after a strong closing quarter last nancial year, is therefore particularly signi cant. The performance of the result during the quarter also shows clear improvement. We report a positive EBITDA of SEK 3.8 million, compared to SEK -10.7 million in the corresponding quarter last year, an improvement of SEK 14.5 million. EBITDA was positively a ected by SEK 6.2 million from the refund of US customs duties previously paid. Excluding the refund, EBITDA amounted to SEK -2.4 million, which also represents a clear improvement compared to the previous year. At the same time, we are seeing a higher gross margin and a lower cost level. Excluding the customs refund, the gross margin was 82%, compared with 80% last year. “We are now seeing how the combination of increased sales, a more focused organization and a lower cost base is beginning to translate into a clear improvement in our nancial performance.” Integrum | Interim Report May-July 2026 2
Page 4
Overall, the development in S1, sales and result shows that the underlying business has strengthened. The combination of higher sales, a more focused organization and the lower cost base we have established over the past year means that continued growth is having an increasingly visible impact on the result. We are not there yet, but the progress shows that we are taking clear steps towards our goal of building a sustainably pro table Integrum. The commercial platform is in place Over the past year we have changed the way Integrum works commercially. We have moved from an approach that depended largely on patients nding their way to our clinics, to a model where we actively create demand, identify potential patients and support them all the way through to treatment. The digital platform we launched in the US in May is now established, and for the rst time it allows us to work in a structured, data- driven way across the entire commercial funnel - from digital activity and patient interest through to quali ed leads and, ultimately, S1 surgery. The next phase is therefore less about building the infrastructure and more about getting the maximum return out of it. Our focus is on driving relevant tra c, improving lead quality and, most importantly, raising conversion throughout the patient journey. Following the launches in the US and Ukraine, work is now under way with Germany, where we plan to launch the platform in the beginning of the second quarter. Stronger commercial organization We are also continuing to strengthen our commercial organization. The US remains our largest and strategically most important market, and building patient ow to our Centers of Excellence is central to our growth. At the same time, we see real opportunities in Europe. We are strengthening our presence in the DACH region and working more closely with clinics and partners to increase the number of patients who gain access to the OPRA Implant System. In Ukraine, we are working towards a more long-term and structured establishment of osseointegration within the country's healthcare system. We have gradually built our local presence and our collaboration with clinics and other relevant partners. Our ambition is to create a lasting structure that can give considerably more patients access to treatment. Innovation creates the next growth platform While we accelerate the commercialization of the OPRA Implant System, we are also continuing to develop the next generation of technology for people living with amputation. Our work in bionics and neural control is of strategic importance to Integrum's long-term development. Through Afyri, we are establishing a clearer structure for advancing this technology and its commercial potential alongside our core business. This gives us a clear dual focus: accelerating the commercial potential of the OPRA Implant System today, while building the technology that can de ne the next generation of advanced prosthetic solutions. We continue as planned The rst quarter con rms that our strategic shift is delivering. S1 volumes are growing, our digital commercial platform is established, our cost base is lower, and we report positive EBITDA for the quarter. After a year of transformation, we have built a stronger and more scalable business, with better conditions for continued growth and improved pro tability. The task now is to keep driving that development with the same focus and high pace. We will reach more patients, improve conversion and drive more S1 surgeries. We have a clear plan, the results con rm it is working, and we are continuing to execute it with our full attention on building a growing and sustainably pro table Integrum. Martin Hillsten / CEO Integrum | Interim Report May-July 2026 3
Page 5
In parallel, Integrum is developing next-generation bionic solutions, where e-OPRA and neural interfaces have the potential to enable advanced intuitive control and sensory feedback between humans and prosthetics in the future. Integrum AB is listed on the Nasdaq First North Growth Market (INTEG B). Key Figures 3 months 12 months Amounts in SEK thousand 31 Jul 2026 31 Jul 2025 30 Apr 2026 Net sales 30 221 23 793 91 385 Net sales growth (%) 27.0 28.9 0.3 Gross margin (%) * 102.3 80.1 77.0 EBITDA 3 837 -10 703 -41 259 Operating pro t/loss 1 309 -12 429 -53 157 Pro t/loss before tax 1 213 -12 540 -53 699 Equity/asset ratio (%) 87.5 86.7 84.5 Number of employees (FTE) at end of period 33 36 32 Equity per share, SEK 6.5 7.9 6.4 Share price on balance sheet date, SEK 8.8 41.7 7.8 Market value on balance sheet date, SEK million 234.1 888.6 209.1 Stage 1 surgeries (S1) US 32 27 116 Stage 1 surgeries (S1) EMEA 16 14 59 Stage 1 surgeries (S1) Total 48 41 175 * Gross margin exceeded 100% in the quarter due to a SEK 6,2 million refund of previously paid U.S. customs duties recognized in cost of goods sold. Adjusted for this item, the gross margin was 82%. Freedom of mobility forevery person Building on osseointegration and next- generation bionics, Integrum develops products and technologies that bring the person and the prosthesis closer together. Integrum is a Swedish medical technology company with roots in the research that laid the foundation for osseointegration. The company develops products and technologies designed to create a more direct and functional connection between the human body and external prostheses. At the center of Integrum's current commercial operations is the OPRA™ Implant System, a prosthetic system anchored directly in the bone, creating a stable connection between the body and the prosthesis and removing the need for a conventional socket. More than 1,000 patients worldwide have been treated with the OPRA™ Implant System. The system is certi ed under the EU Medical Device Regulation (MDR) and approved by the U.S. Food and Drug Administration (FDA). In the US, OPRA™ is the only FDA-approved bone-anchored implant system developed speci cally for people who have undergone amputation. Integrum | Interim Report May-July 2026 4
Page 6
Stacey lives with the OPRA Implant System Stacey is not particularly good at sitting still. She runs her own salon, loves horses and riding, and wants to be involved where the action is. After her leg amputation, the conditions changed. Today, after treatment with Integrum's OPRA Implant System, her daily life looks completely di erent. For years, the traditional socket prosthesis was an enemy. It helped her get from one side of the room to the other, but not to live the life she wanted to live. The skin was constantly bruised and each day life was lled with wounds, ointments and pain. However, giving up was never an option for Stacey. From socket prosthesis to bone-anchored prosthesis Together with her care team, Stacey chose Integrum's OPRA Implant System, in which the prosthesis attaches directly to an implant anchored in the bone. A year and a half later, she describes a life that looks almost nothing like the one she had before. She can feel the ground beneath her again — but the biggest di erence lies in everything she no longer has to think about. Back in the middle of everything Stacey runs her salon, spends time at the stable, and switches between ats, heels, and riding boots depending on what the day holds. Small things on their own, but together something much bigger — everyday life no longer revolves around the prosthesis. It showed most clearly when her daughter was competing at a riding event in South Africa. Stacey went with her. Before the treatment, a trip like that would have been hard to imagine. The biggest change is not how she walks, but how little room the prosthesis takes up in her life. Now, her focus lies elsewhere. On the clients in the salon. On the horses. On which shoes to wear. On the next trip with her daughter. On life. Watch Stacey's story Meet Stacey and hear her tell in her own words about life before and after treatment with OPRA Implant System (www.opraimplantsystem.com). Integrum | Interim Report May-July 2026 5
Page 7
Meet Louise Wåhlin – CFO of Integrum You stepped into the CFO role during a very eventful period. How would you describe your first year at Integrum? It's been eventful, to say the least, but above all a lot of fun. When I joined Integrum, the company already had a great deal going for it: outstanding technology, deep expertise, and products that make a real di erence. What we needed was to get better at prioritizing. Much of the year has therefore been about building a more stable foundation to grow from. We've worked on our cost base, organization, governance, and transparency, alongside a bidding process, a capital raise, and changes to the board and management. We're not done, I don't think a growing company ever should feel done, but we've turned strategy into concrete priorities and ways of working. What milestones are you most proud of? It is easy to start with the big, visible milestones. We have brought down our underlying cost level, completed a heavily oversubscribed rights issue, and reached the highest number of S1 surgeries in the company's history. We've also taken important commercial steps, not least in the US and Ukraine. But I am just as proud of what has happened behind the scenes. We have developed how we work, built a new nance team, and begun to change the way we communicate with our shareholders. Step by step, we're building an Integrum that can grow without cost and complexity growing at the same pace. What is at the top of your agenda? The short answer is pro table growth. My part in that is creating the right conditions for it. We have laid a more stable foundation, and now we want it to pay o — investing where we see the greatest impact and making sure the business can scale as volumes grow. There are markets with real potential, and we need to be ready for them without costs and complexity growing at the same pace. What are you looking forward to the most? What I am looking forward to most is showing the market what a remarkable company Integrum is, and the potential we have here. It is hard not to be fascinated by the technology and where it can take us. Developments in bionics and neural interfaces are opening up entirely new possibilities — not only to restore lost function, but perhaps to go further still. The human body may not always de ne the limits of what is possible. Integrum | Interim Report May-July 2026 6
Page 8
First quarter 2026/27 (May-July) Net Sales Net sales amounted to SEK 30,221 thousand (23,793), corresponding to an increase of 27.0% compared to the previous year. Net sales include SEK 3.2 million related to clinical studies and associated research activities, alongside revenue from the company’s regular product sales. In xed exchange rates, the growth was 28%. In the US, net sales amounted to SEK 23,513 thousand (19,346), an increase of 22%. On other markets (EMEA), net sales amounted to SEK 6,708 thousand (4,447), an increase of 51%. The US thus accounted for 78% (81%) of the Group's net sales and other markets (EMEA) for 22% (19%). For revenue per market, see note 3. Costs and Results Cost of goods sold amounted to SEK 704 thousand (-4,732). The quarter includes repayments of SEK 6.2 million of previously paid US customs duties, which have been reported as a reduction in cost of goods sold. Excluding this e ect, the gross margin was 82% (80%). Other external costs decreased to SEK -14,996 thousand (-17,962) and personnel costs to SEK -12,070 thousand (-12,513). During the quarter, Integrum had costs of approximately SEK -1.2 million related to the work of developing Afyris' business, products, and commercial focus, as well as approximately SEK -0.5 million linked to the development of the company's external communication, including new digital platforms and report formats. Currency e ects a ected operating pro t by net SEK -939 thousand (-329) and depreciation amounted to SEK -2,528 thousand (-1,726). Operating pro t amounted to SEK 1,309 thousand (-12,429). Cash flow Cash ow from operating activities before changes in working capital amounted to SEK 4,964 thousand (-10,716). Changes in working capital a ected cash ow by SEK -7,123 thousand (1,201), mainly due to reduced trade payables. Cash ow from operating activities thus amounted to SEK -2,159 thousand (-9,515). Investments during the quarter amounted to SEK 1,985 thousand (2,484) and mainly concerned continued product development within the Group's R&D operations. The period's cash ow amounted to SEK -4,055 thousand (-12,408). Financial position and continued operations At the end of the period, the Group's liquid funds amounted to SEK 15,006 thousand and equity to SEK 174,188 thousand. The Board continuously evaluates the Group's liquidity, cash ow, and nancing needs in the short and long term. During the past year, Integrum has implemented cost reductions and organizational adjustments, as well as strengthened the nancial position through completed nancing measures. Net sales, SEK million 18.5 21.8 23.7 27.1 23.8 22.3 20.2 25.1 30.2 Q1 24/25 Q1 25/26 Q1 26/27 Operating pro t/loss, SEK million -12.0 -11.3 -7.4 -11.7 -12.4 -11.1 -9.5 -20.1 1.3 Q1 24/25 Q1 25/26 Q1 26/27 Integrum | Interim Report May-July 2026 7
Page 9
Other information Parent company Integrum AB (publ), organization number 556407–3145, is the parent company of the Integrum Group and is headquartered in Mölndal. Significant risks and uncertainty factors Integrum continuously works to identify, evaluate, and manage risks in various systems and processes. Risk analyses are performed on an ongoing basis in the ordinary course of business and in connection with major activities. The most signi cant strategic and operational risks a ecting the Group's operations and industry are described in the company's annual report. The main risks and uncertainties include, among other things, market risks, seasonal variations, currency risks, permits and certi cations, product quality, supplier dependence, and liquidity risks. The described risks are deemed to be largely unchanged. Significant events during the period In May, Integrum launched a new digital patient portal in the US with the aim of increasing patient ow and awareness of the OPRA Implant System. The platform is intended to provide better support to patients and their families, as well as enable more structured follow-up and guidance of potential patients to the right care unit. In June, Integrum announced that the company intends to gather all its activities in bionics, including e-OPRA, into a new wholly- owned subsidiary under the name Afyri. The purpose is to create better conditions for continued development and commercialization, as well as enable new nancing and collaboration opportunities. In June, Integrum received a refund of approximately SEK 2.6 million from the US customs authorities regarding previously paid customs duties that, after administrative review, were deemed not applicable to parts of the company's imports. In June, Integrum announced that Ukraine's Ministry of Health had completed the preparatory work on the proposal to introduce osseointegration as part of the national healthcare for individuals with amputations and submitted the proposal to the country's government for decision. In July, Integrum received an additional refund of approximately SEK 3.6 million regarding previously paid US customs duties. Together with the refund in June, the received refunds during the quarter amounted to approximately SEK 6.2 million. Significant events after the balance sheet date In August, the Election Committee was appointed ahead of Integrum AB's Annual General Meeting on September 29, 2026. The Election Committee consists of Jakob Have, appointed by Nordic Compound Invest A/S and Chairman of the Election Committee, Rickard Brånemark, appointed by Pericardium AB, and Kristofer Westergren, appointed in his capacity as a shareholder. Integrum | Interim Report May-July 2026 8
Page 10
Shareholder Structure The ten largest shareholders as of July 31, 2026, are listed in the table below Name Number of shares Capital (%) Rickard Brånemark 6 447 086 24.2 Nordic Compound Invest A/S 2 981 927 11.2 Avanza Pension 1 823 784 6.8 Nordnet Pensionsförsäkring 1 564 360 5.9 Futur Pension 647 389 2.4 Martin Olof Brage Larsén 625 000 2.3 Marcus Martayan 549 000 2.1 Henrik Hedlund 500 000 1.9 Kristofer Westergren 499 740 1.9 Fredrik Rundqvist 428 565 1.6 Total Ten Largest Shareholders 16 066 851 60.2 Others 10 601 059 39.8 Total 26 667 910 100.0 Personnel and organisation At the end of the period, the number of employees was 33 (36) people (FTE), of which 17 (19) were women and 16 (17) were men. Annual Meeting 2026 The Annual General Meeting of Integrum AB (publ) will be held on September 29, 2026. The notice to the Annual General Meeting will be published separately and will be available on the company's website. Trading Venue and Certified Adviser Integrum AB's B-share is listed on Nasdaq First North Growth Market Stockholm under the ticker symbol INTEG B. The company's Certi ed Adviser is DNB Carnegie Investment Bank AB. Review This interim report has not been reviewed by the company's auditor. The interim report has been prepared in Swedish and translated into English. In the event of any discrepancies between the language versions, the Swedish version shall prevail. Integrum | Interim Report May-July 2026 9
Page 11
Assurance by the Board of Directors and the CEO The Board of Directors and the Managing Director assure that the interim report provides a complete and accurate overview of the Group's and the Parent Company's operations, position and results, and describes the signi cant risks and uncertainties that the Parent Company and the companies included in the Group face. Mölndal on September 3, 2026 Rickard Brånemark Chair of the Board Henric Carlsson Board Member Torben Jörgensen Board Member Anette Lindqvist Board Member Fredrik Rundqvist Board Member Kristofer Westergren Board Member Martin Hillsten CEO Presentation for Investors, analysts and the media The interim report for May–July 2026 will be presented in a digital webcast on September 3 at 10:00 a.m. CEST. President and CEO Martin Hillsten and CFO Louise Wåhlin will present the report and comment on the Group's performance during the period. The presentation will be held in Swedish and will be followed by a Q&A session. To participate in the presentation, please follow the link below: https://www. nwire.tv/webcast/integrum/q1− 2026/ Upcoming reports 3 December 2026 Interim report August-October 2026/2027 4 March 2027 Interim report November-January 2026/2027 10 June 2027 Year-End report 2026/2027 Please refer any questions to Martin Hillsten, CEO martin.hillsten@integrum.se Louise Wåhlin, CFO louise.wahlin@integrum.se Integrum AB Org. nr. 556407–3145 Gemenskapens gata 9 431 53 Mölndal integrum.se info@integrum.se Integrum | Interim Report May-July 2026 10
Page 12
Condensed Consolidated Statement ofComprehensive Income 3 months 12 months Amounts in SEK thousand Note 31 Jul 2026 31 Jul 2025 30 Apr 2026 Net sales 3 30 221 23 793 91 385 Work performed by company for own use and capitalized 872 1 040 4 708 Other operating income 4 1 258 - 45 Total Revenues 32 351 24 834 96 138 Cost of goods sold * 704 -4 732 -21 017 Other external costs * 5 -14 996 -17 962 -64 513 Personnel expenses -12 070 -12 513 -50 185 Depreciation and impairment of xed assets -2 528 -1 726 -11 898 Other operating expenses 4 -2 152 -329 -1 681 Total expenses -31 042 -37 262 -149 294 Operating pro t/loss 1 309 -12 429 -53 156 Financial income 1 21 72 Financial expenses -97 -132 -614 Net nancial items -96 -111 -543 Pro t/loss before tax 1 213 -12 540 -53 699 Income tax -341 2 579 7 361 Pro t/loss for the period 6 872 -9 961 -46 338 Other comprehensive income: Items that may be reclassi ed for the net pro t/loss for the period Exchange rate di erences when translating foreign operations 1 309 410 2 751 Other comprehensive income for the period 1 309 410 2 751 Total comprehensive income for the period 2 181 -9 552 -43 587 3 months 12 months Amounts in SEK Note 2026/2027 2025/2026 2026/2027 Earnings per share before dilution 6 0.03 -0.47 -1.98 Earnings per share after dilution ** 6 0.03 -0.47 -1.98 * The comparative gures have been reclassi ed regarding sales commissions and warehouse cost, which have been moved from cost of goods sold to other external costs. The reclassi cation does not a ect the operating result. ** The comparative gure for earnings per share after dilution has been adjusted to take into account that outstanding warrants were antidilutive during the comparative period. Integrum | Interim Report May-July 2026 11
Page 13
Condensed Consolidated Statement ofFinancial Position 31 Jul 30 apr Amounts in SEK thousand Note 2026/27 2025/26 2025/26 ASSETS Non-current assets Intangible assets Capitalized expenditure for development work 66 860 60 904 66 533 Concessions, patents, licences, trademarks 80 136 92 Total intangible assets 66 940 61 041 66 624 Tangible assets Machines, equipment and furniture 5 978 581 6 423 Total tangible assets 5 978 581 6 423 Right of use 2 482 4 137 2 896 Deferred tax assets 43 720 39 639 43 975 Total non-current assets 119 120 105 398 119 918 Current assets Inventories Finished goods and goods for resale 30 256 29 600 29 444 Total inventories 30 256 29 600 29 444 Current receivables Accounts receivable 28 995 26 501 28 615 Tax assets 962 451 903 Other receivables 2 104 2 138 2 113 Prepaid expenses and accrued income 2 703 2 507 3 547 Total current receivables 34 764 31 597 35 178 Liquid assets 15 006 27 191 19 061 Total current assets 80 026 88 388 83 683 TOTAL ASSETS 199 146 193 786 203 601 EQUITY Share capital 1 867 1 493 1 867 Other contributed capital 301 090 263 531 301 090 Reserves -17 029 -20 679 -18 338 Retained earnings, including pro t/loss for the period -111 741 -76 237 -112 613 Total equity 174 188 168 109 172 007 LIABILITIES Long-term liabilities Lease liabilities 939 2 737 1 398 Total non-current liabilities 939 2 737 1 398 Current liabilities Accounts payable 3 506 7 047 8 592 Lease liabilities 1 799 1 698 1 773 Other current liabilities 13 931 6 409 15 397 Accrued expenses and deferred income 4 785 7 786 4 435 Total current liabilities 24 019 22 940 30 196 TOTAL EQUITY AND LIABILITIES 199 146 193 786 203 601 Integrum | Interim Report May-July 2026 12
Page 14
Condensed Consolidated Statement ofChanges In Equity Amounts in SEK thousand Share capital Other contributed capital Reserves Retained earnings, including pro t/loss for the period TOTAL EQUITY Opening balance on 1 May 2025 1 493 263 531 -21 089 -66 275 177 661 Pro t/loss for the period 0 0 0 -9 962 -9 962 Other comprehensive income for the period 0 0 410 0 410 Total comprehensive income - - 410 -9 962 -9 552 Transactions with shareholders New share issue - - 0 0 0 Warrants 0 - 0 0 0 Total transactions with shareholders - - - - 0 Closing balance on 31 July 2025 1 493 263 531 -20 679 -76 237 168 109 Amounts in SEK thousand Share capital Other contributed capital Reserves Retained earnings, including pro t/loss for the period TOTAL EQUITY Opening balance on 1 May 2026 1 867 301 090 -18 338 -112 613 172 007 Pro t/loss for the period 0 0 0 872 872 Other comprehensive income for the period 0 0 1 309 0 1 309 Total comprehensive income 0 0 1 309 872 2 181 Transactions with shareholders New share issue 0 0 0 0 0 Warrants 0 0 0 0 0 Total transactions with shareholders 0 0 0 0 0 Closing balance on 31 July 2026 1 867 301 090 -17 029 -111 741 174 188 Integrum | Interim Report May-July 2026 13
Page 15
Condensed Consolidated Statement of CashFlows 3 months 12 months Amounts in SEK thousand Note 31 Jul 2026 31 Jul 2025 30 Apr 2026 Operating activities Pro t/loss before nancial items 1 309 -12 429 -53 157 Interest received 1 21 72 Interest paid -97 -132 -614 Taxes paid -86 - - Adjustments for items not included in cash ow 3 837 1 824 18 795 Cash ow from operating activities before change in working capital 4 964 -10 716 -34 904 Cash ow from changes in working capital Changes in inventories -812 -2 076 -11 503 Changes in operating receivables 414 2 429 -1 316 Changes in operating liabilities -6 725 849 6 699 Cash ow from changes in working capital -7 123 1 201 -6 120 Investing activities Purchase of assets -1 985 -2 484 -16 940 Cash ow from investing activities -1 985 -2 484 -16 940 Financing activities New share issue - - 37 621 Warrants - - 312 Leases -434 -409 -1 673 Net change in credit facilities 522 - 1 167 Cash ow from nancing activities 89 -409 37 426 Cash ow for the period -4 055 -12 408 -20 539 Liquid assets at the start of the period 19 061 39 599 39 599 Liquid assets at end of period 15 006 27 191 19 061 Integrum | Interim Report May-July 2026 14
Page 16
Condensed Parent Company IncomeStatement 3 months 12 months Amounts in SEK thousand Note 31 Jul 2026 31 Jul 2025 30 Apr 2026 Net sales 18 768 16 039 26 511 Work performed by company for own use and capitalized 872 1 040 4 228 Other operating income 3 648 1 308 4 483 Total Revenues 23 288 18 387 35 222 Cost of goods sold 226 -6 312 -17 618 Other external costs 5 -9 344 -11 145 -39 430 Personnel expenses -8 240 -7 643 -28 828 Depreciation and impairment of xed assets -1 896 -1 307 -7 465 Other operating expenses 5 -2 152 -1 573 -41 278 Total expenses -21 406 -27 981 -134 617 Operating pro t/loss 1 882 -9 594 -99 395 Interest income and similar income statement items 6 251 2 521 16 306 Interest expenses and similar income statement items -1 969 -62 -14 398 Total pro t/loss from nancial items 4 281 2 459 1 908 Pro t/loss after nancial items 6 163 -7 135 -97 487 Tax on pro t for the period - 1 470 20 057 Pro t/loss for the period 6 163 -5 665 -77 430 Integrum | Interim Report May-July 2026 15
Page 17
Condensed Parent Company Balance Sheet 31 Jul 30 apr Amounts in SEK thousand Note 2026/27 2025/26 2025/26 ASSETS Non-current assets Capitalized expenditure for development work 66 860 61 865 66 533 Concessions, patents, licences, trademarks 80 136 92 Total intangible assets 66 940 62 001 66 624 Machines, equipment and furniture 4 678 559 4 981 Total tangible assets 4 678 559 4 981 Financial assets Participations in group companies 615 590 590 Receivables from group companies 92 530 100 258 91 285 Deferred tax assets 35 027 16 440 35 027 Total nancial assets 128 171 117 287 126 901 Total non-current assets 199 789 179 847 198 507 Current assets Inventories Finished goods and goods for resale 23 716 17 259 23 257 Total inventories 23 716 17 259 23 257 Current receivables Accounts receivable 6 521 7 224 6 037 Receivables from group companies - 28 171 - Tax assets 903 428 846 Other receivables 2 104 2 138 2 113 Prepaid expenses and accrued income 1 804 1 978 2 595 Total current receivables 11 332 39 940 11 591 Cash and bank balances 8 272 16 512 11 330 Total current assets 43 319 73 710 46 179 TOTAL ASSETS 243 109 253 558 244 686 EQUITY AND LIABILITITES EQUITY Restricted equity Share capital 1 867 1 493 1 867 Statutory reserve 5 5 5 Fund for development expenditure 66 860 61 865 66 533 Total restricted equity 68 732 63 363 68 404 Non-restricted equity Share premium reserve 299 616 266 055 302 229 Pro t or loss from previous period -170 085 -91 658 -94 940 Pro t/loss for the period 6 163 -5 665 -77 430 Total non-restricted equity 135 695 168 732 129 859 TOTAL EQUITY 204 426 232 095 198 263 LIABILITIES Current liabilities Accounts payable 2 776 6 109 7 487 Payables from group companies 22 866 - 25 336 Other current liabilities 9 383 8 141 10 271 Accrued expenses and deferred income 3 657 7 212 3 329 Total current liabilities 38 682 21 462 46 423 TOTAL EQUITY AND LIABILITIES 243 109 253 558 244 686 Integrum | Interim Report May-July 2026 16
Page 18
Note 1. Accounting policies Integrum applies International Financial Reporting Standards (IFRS Accounting Standards) as adopted by the European Union. The accounting principles and de nitions are applied consistently with those described in Integrum's Annual Report 2024/2025, available on Integrum's website. During the 2025/2026 nancial year, the Company changed its inventory valuation method from FIFO to the standard cost method. The change is not expected to have any material impact on the Company's nancial position or results of operations and, accordingly, no restatement of comparative gures has been made. The Company will adapt its nancial reporting to IFRS 18 ahead of the upcoming nancial year. The assessment is that the standard will primarily a ect the presentation and disclosures in the nancial statements. Integrum has assessed that certain intercompany loans within the Group constitute part of a net investment in a foreign operation in accordance with IAS 21, as settlement of these loans is neither planned nor likely to occur in the foreseeable future. Consequently, exchange di erences arising on these loans are recognized in other comprehensive income, as part of the exchange di erences arising on the translation of foreign operations, for as long as the conditions in IAS 21 are deemed to be met. This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act (Årsredovisningslagen). The Parent Company applies the Swedish Annual Accounts Act and RFR 2 Accounting for Legal Entities. Unless otherwise stated, all amounts are presented in thousands of Swedish kronor (TSEK). Figures in parentheses refer to the corresponding period of the previous year. Note 2. Estimates and assumptions The Group makes estimates and assumptions about the future. By de nition, the resulting accounting estimates will rarely correspond exactly to actual outcomes. The estimates and assumptions that involve a signi cant risk of material adjustments to the carrying amounts of assets and liabilities during the next nancial year are outlined below. (a) Intangible assets Development expenditures directly attributable to the development of the Group's products are subject to management's judgments and estimates in assessing whether the criteria for capitalization as intangible assets are satis ed. (b) Impairment test of capitalized development expenditures The Group performs an annual impairment test of capitalised development expenditures in accordance with the accounting policy described in Note 1. The recoverable amounts of the cash-generating units have been determined using value-in-use calculations. (c) Deferred tax assets The Parent Company and the Group’s U.S. subsidiaries reported tax loss carryforwards in their most recent tax lings. Management has assessed that su cient taxable pro ts will be generated in the foreseeable future to enable the utilization of these tax loss carryforwards. Consequently, as of 30 April 2026, the Company concluded that recognition of a deferred tax asset relating to the available tax loss carryforwards was appropriate. The Group also has unrealized pro ts in inventory arising from transactions between the Parent Company in Sweden and its U.S. subsidiary. Management assesses that these inventories will be sold externally and that the related deferred tax asset will therefore be realized. Accordingly, this deferred tax asset has also been recognized in the statement of nancial position. Note 3. Revenue by market 3 months 12 months Amounts in SEK thousand 2026/27 2025/26 2025/26 US 23 513 19 346 72 466 EMEA 6 708 4 447 18 919 Total 30 221 23 793 91 385 Integrum | Interim Report May-July 2026 17
Page 19
Note 4. Other operating income/expenses 3 months 12 months Amounts in SEK thousand 2026/27 2025/26 2025/26 Exchange gains 1 213 1 255 4 386 Exchange losses -2 152 -1 584 -6 068 Lease income 45 - - Total -894 -329 -1 681 Note 5. Related party transactions Transactions with key individuals in senior positions During the period, the Company received technical expert support, clinical services and strategic consulting services from entities related to Board members and former Chief Executive O cers, amounting to SEK 1,090 thousand (1,419). Of this amount, SEK 1,090 thousand relates to compensation paid to entities associated with the Chairman of the Board and a major shareholder. The compensation relates to clinical participation in S1 surgeries using the Company's products, international training and educational activities, development of surgical instruments, and sales and operational support. The amounts also include reimbursement of travel expenses incurred in connection with these assignments. The transactions were conducted on arm's length terms and were approved by the Board of Directors without the participation of the concerned Board member. The related costs have been recognized under other external expenses. Related party relationships The Parent Company engages in transactions with its subsidiaries relating to intra-group services and transfer pricing adjustments. These transactions are conducted on market terms and in accordance with the arm’s length principle. Note 6. Earnings per share 3 months 12 months 2026/27 2025/26 2025/26 Consolidated pro t/loss for the period, SEK thousand 872 -9 961 -46 338 Weighted average number of shares before dilution 26 667 910 21 334 328 23 423 923 Outstanding shares at period-end 26 667 910 21 334 328 26 667 910 Dilution e ect of option programs - - - Weighted average number of shares after dilution 26 667 910 21 334 328 23 423 923 Earnings per share before dilution 0.03 -0.47 -1.98 Earnings per share after dilution * 0.03 -0.47 -1.98 * The comparative gure for diluted earnings per share has been adjusted to re ect that the outstanding share warrants were anti- dilutive during the comparative period. Share warrant program As of the reporting date, 1,325,791 warrants were outstanding under the Group’s incentive programs. In the calculation of diluted earnings per share, consideration is given to the exercise price of the warrants in relation to the average share price during the period, as well as the pro t or loss for the period. If the period result is negative, or if the exercise price of the warrants exceeds the average share price, the warrants are considered anti-dilutive and are therefore excluded from the calculation. All outstanding warrants were anti-dilutive during the period and have therefore not been included in the calculation of diluted earnings per share. Integrum | Interim Report May-July 2026 18
Page 20
Definitions Integrum applies ESMA's guidelines for alternative key gures. In this report, certain nancial key gures are presented, including alternative key gures that are not de ned according to IFRS. The company believes that these key gures are an important complement because they facilitate a better assessment of the company's nancial development. These nancial key gures should not be assessed separately or considered as a replacement for result measures calculated in accordance with IFRS. Furthermore, such key gures, as de ned by Integrum, should not be compared with other key gures with similar designations used by other companies. This is because the key gures below are not always de ned in the same way and that other companies may calculate them in a di erent way than Integrum. Financial Definitions Net Sales Growth The percentage increase in net sales compared to the previous period. Operating Result (EBIT) Result before nancial items and tax. Operating Margin (EBIT) (%) EBIT as a percentage of the period's net sales. EBITDA A measure of the company's operating result before interest, tax, depreciation and amortization Equity/asset ratio (%) Equity at the end of the period in relation to the balance sheet total at the end of the period. Equity per Share Equity divided by the number of shares at the end of the period. Employees The number of employees at the end of the period. FTE Full-Time Equivalent. Number of employees converted to full-time equivalents, where part-time employees are counted proportionally according to their employment rate. Other definitions EMEA Europe, Middle East and Africa. Geographic region for sales and business follow-up. S1 Surgeries (Stage 1) The rst of two surgeries in the treatment with the OPRA Implant System, when the titanium implant is operated into the bone. OPRA Implant System Integrum's bone-anchored prosthetic system for amputees. The name stands for Osseoanchored Prostheses for the Rehabilitation of Amputees. The prosthesis is connected directly to a titanium implant that is anchored in the skeleton, instead of being worn in a socket on the stump. eOPRA Integrum's next-generation osseointegrated implant system that enables direct communication between the prosthesis, muscles and nerves for improved control and sensory feedback. Osseointegration The biological process where bone tissue grows together with a titanium implant so that the implant becomes a permanent part of the skeleton. Transfemoral Amputation above the knee. PMA (Premarket Approval) The US FDA's strictest approval process for medical devices. Integrum | Interim Report May-July 2026 19